The role of striatal glutamatergic system in haloperidol-induced dopamine receptor supersensitivity and effects of monosialoganglioside GM1

Pharmacology Biochemistry and Behavior

Volumn 58, Issue 4, 1997, Pages 903-907

  Schroeder, H ^a   Schroeder, U ^a   Sabel, B A ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

(3H) D Aspartate release; Binding sites; Dopamine; Ganglioside; Glutamate; Striatum

Indexed keywords

ASPARTIC ACID; BUTACLAMOL; DOPAMINE RECEPTOR; GANGLIOSIDE GM1; GLUTAMIC ACID; HALOPERIDOL; SPIPERONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; MALE; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY; SUPERSENSITIVITY;

ANIMALS; ASPARTIC ACID; DOPAMINE ANTAGONISTS; G(M1) GANGLIOSIDE; GLUTAMIC ACID; HALOPERIDOL; MALE; NEOSTRIATUM; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE; RECEPTORS, GLUTAMATE; SPIPERONE;

EID: 0031405981     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00026-9     Document Type: Article

References (24)

1. Cheramy A., Desce J. M., Godeheu G., Glowinski J. Presynaptic control of dopamine synthesis and release by excitatory amino acids in rat striatal synaptosomes. Neurochem. Int. 25:1994;145-154.
2. Di Chiara G., Morelli M., Consolo S. Modulatory functions of neurotransmitters in the striatum. ACh/Dopamine/NMDA interactions Trends Neurosci. 17:1994;228-233.
3. Ellis Y., Davies J. A. The effects of sigma ligands on the release of glutamate from rat striatal slices. Naunyn Schmiedebergs Arch. Pharmacol. 350:1994;143-148.
4. + channels by GM1 ganglioside. Biochem. Biophys. Res. Commun. 200:1994;1341-1345.
5. Fink J. S. Neurobiology of basal ganglia receptors. Clin. Neurosci. 1:1993;27-35.
6. Fonnum F., Storm-Mattisen J., Divac I. Biochemical evidence for glutamate as neurotransmitter in corticostriatal and cortico-thalamic fibers in rat brain. Neuroscience. 6:1981;863-873.
7. Hernandez L., Tucci S., Guzman N., Paez X. In vivo monitoring of glutamate in the brain by microdialysis and capillary electrophoresis with laser-induced fluorescence detection. J. Chromatogr. A. 652:1993;393-398.
8. Köhler U., Schröder H., Augustin W., Sabel B. A. A new animal model of dopamine supersensitivity using subcutaneous implantation of haloperidol releasing polymers. Neurosci. Lett. 170:1994;99-102.
9. Kulkarni S. K., Verma A. Glutamate-dopamine receptor interaction in neuropsychiatric disorders. Drugs Today. 27:1991;255-270.
10. Leysen J. E. H., Gommeren W., Laduron P. M. Spiperone. A ligand of choice for neuroleptic receptors - 1 Kinetics and characteristics of in vitro binding. Biochem. Pharmacol. 27:1978;307-316.
11. Lipartiti M., Lazzaro A., Manev H. Ganglioside derivative LIGA 20 reduces NMDA neurotoxicity in neonatal rat brain. Neuroreport. 3:1992;919-921.
12. Lowry O. H., Rosebrough R. N., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
13. 2 dopamine receptors are located on striatal glutamatergic nerve terminals. J. Pharmacol. Exp. Ther. 247:1988;680-684.
14. Sabel B. A. Anatomic mechanisms whereby ganglioside treatment induces brain repair; What do we really know? Stein D. G., Sabel B. A. Pharmacological approaches to the treatment of brain and spinal cord injury. 1988;167-193 Plenum Publishing Corporation, New York.
15. Sabel B. A., Dunbar G. L., Butler W. M., Stein D. G. GM1 ganglioside stimulates neuronal reorganisation and reduce rotational asymmetry after hemitransections of the nigrostriatal pathway. Exp. Brain Res. 60:1985;27-37.
16. Schröder H., Becker A., Lössner B. Glutamate binding to brain membrane is increased in Pentylenetetrazol-kindled rats. J. Neurochem. 60:1993;1007-1011.
17. Schröder H., Reymann K. G. N-Methyl-d-aspartate (NMDA) stimulates the release of dopamine from rat hippocampal slices. Biomed. Biochim. Acta. 49:1990;281-284.
18. Schröder U., Schröder H., Augustin W., Sabel B. A. Haloperidol induced behavioral supersensitivity is increased in rats by GM1 ganglioside treatment without affecting spiroperidol binding. J. Pharmacol. Exp. Ther. 271:1994;1193-1196.
19. Sherman A. D., Davidson A. T., Baruah S., Hegwood T. S., Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neurosci. Lett. 121:1991;77-80.
20. Shifman M. The effect of gangliosides upon recovery of aspartate/glutamatergic synapses in striatum after lesions of the rat sensorimotor cortex. Brain Res. 568:1991;323-324.
21. Skaper S. D., Leon A., Toffano G. Ganglioside function in the development and repair of the nervous system. Mol. Neurobiol. 3:1989;173-199.
22. Svennerholm L. Chromatographic separation of human brain gangliosides. J. Neurochem. 10:1963;613-623.
23. Umeda Y., Sumi T. Evoked release of endogenous amino acids from rat striatal slices and its modulation. Eur. J. Pharmacol. 163:1989;291-297.
24. Zukin S. R., Young A. B., Snyder S. H. Gamma-aminobutyric acid binding to receptor sites in the central nervous system. Proc. Natl. Acad. Sci. USA. 71:1974;4802-4807.